Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2020-03-17 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1505 characters) and contains the header 'RNS Number : 4853G'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. This is a general regulatory announcement concerning market operations rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or CAP, the most appropriate fallback category is Regulatory Filings (RNS).
2020-03-17 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1488 characters) and contains an 'RNS Number' header, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service. The content specifically details a 'Price Monitoring Extension' for an auction call period. This type of operational market notice, which does not fit into specific financial reporting categories (like 10-K, ER, or IR), is best classified under the general regulatory announcement category, RNS, as per the definitions and the 'Menu vs Meal' rule (it's an announcement, not a full report).
2020-03-17 English
AEGIS-H2H study update
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content discusses an 'AEGIS-H2H study update' and clarifies previous statements regarding clinical trial results (non-inferiority analysis). This type of material—a specific, timely update on clinical data, regulatory implications, and internal review processes—is characteristic of a general regulatory announcement rather than a comprehensive financial report (like 10-K or IR) or a specific management/governance filing. Since it is a formal announcement released through the RNS system, and it doesn't fit neatly into the more specific categories like ER, DIV, or MANG, the most appropriate classification is the general regulatory filing category.
2020-03-17 English
Investor Presentation
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated March 6, 2020. The content announces that Shield Therapeutics plc will be presenting at the Hardman & Co. Investor Forum. It details the time, location, and purpose of the presentation, explicitly stating, 'No new material information will be disclosed at either event'. This structure—an announcement about an upcoming presentation or event, often disseminated via an official news service like RNS—points towards a general regulatory announcement rather than a specific financial report (like 10-K, IR, or ER) or a presentation document itself (IP). Since it is a formal announcement disseminated through the London Stock Exchange's news service (RNS), and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory filing category.
2020-03-06 English
Block Listing Application
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and explicitly states it is from 'Shield Therapeutics plc' dated '02 March 2020'. The content details an application for a 'Block Listing' of 2,500,000 ordinary shares to be admitted to trading on the London Stock Exchange, referencing various internal share schemes. This is a specific corporate action announcement made via the Regulatory News Service (RNS). Since it is a general regulatory announcement that doesn't fit into the more specific categories like DIV, CAP, or DIRS, the most appropriate classification is the general regulatory filing category.
2020-03-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled with 'RNS Number' and contains the standard format for a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the core content is a specific regulatory filing about share ownership changes, making MRQ the most precise classification over the general RNS fallback.
2020-02-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.